AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:21 2024-04-16 am EDT			5-day change	1st Jan Change
10,878 ^GBX	-1.32%		+1.59%	+2.62%

03:14pm	Market sentiment sours
03:03pm	ASTRAZENECA : Deutsche Bank returns to 'Hold	CF

ASTRAZENECA : Goldman Sachs maintains a Sell rating

July 21, 2020 at 06:47 am EDT

Keyur Parekh from Goldman Sachs retains his negative opinion on the stock with a Sell rating. The target price remains set at GBX 6000.

Latest news about AstraZeneca PLC

Market sentiment sours	09:14am
ASTRAZENECA : Deutsche Bank returns to 'Hold	09:03am	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	07:52am	MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	07:00am	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	05:50am	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	05:31am
RBC raises Admiral; Barclays cuts Phoenix Group	04:50am	AN
AstraZeneca: improvements in biliary tract cancer	04:33am	CF
AstraZeneca's hails Imfinzi survival data on cancer form	03:40am	AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial	02:30am	MT
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF
ASTRAZENECA : Barclays reiterates its Buy rating	Apr. 15	ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices	Apr. 14	MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	Apr. 12
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector	Apr. 12	MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval	Apr. 11	DJ
AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot	Apr. 11	RE
AstraZeneca shareholders approve 2024 pay policy at AGM	Apr. 11	RE
European Equities Close Lower on Thursday as ECB Leaves Interest Rates Unchanged	Apr. 11	MT
FTSE 100 edges lower as financials drag	Apr. 11	RE
FTSE 100 Closes Down 0.5% Dragged by Financial Stocks After ECB Holds Rates	Apr. 11	DJ

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

137.3 USD

Average target price

162.5 USD

Spread / Average Target

+18.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+2.62%	213B
ELI LILLY AND COMPANY	+27.62%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-8.26%	356B
MERCK & CO., INC.	+15.20%	320B
ABBVIE INC.	+5.39%	286B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.94%	142B
SANOFI	-3.31%	116B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Goldman Sachs maintains a Sell rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals